Revance Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss

The total revenue of RVNC for the last quarter is 65.39 M USD, and it's 25.90% higher compared to the previous quarter. The net income of Q2 24 is -37.47 M USD.